Cerevel Therapeutics Holdings (CERE) Prices 14M Share Offering at $25/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. AXP
7. TMUS
8. SPY
9. CVS
10. UNH

Go back to Cerevel Therapeutics Holdings (CERE) Prices 14M Share Offering at $25/sh

Cerevel Therapeutics Holdings (CERE) Cerevel Therapeutics Holdings (NASDAQ: CERE) 30-day option implied volatility at 143 on more puts than calls

July 2, 2021 4:42 AM EDT

Cerevel Therapeutics Holdings (NASDAQ: CERE) 30-day option implied volatility is at 143; compared to its 52-week range of 83 to 345. Call put ratio 1 call to 2 puts.

... More

Cerevel Therapeutics Holdings (CERE) call put ratio 1 call to 2 puts after sharp rally

July 1, 2021 3:55 PM EDT

Cerevel Therapeutics Holdings (NASDAQ: CERE) 30-day option implied volatility is at 140; compared to its 52-week range of 83 to 345. Call put ratio 1 call to 2 puts.

... More

Pre-Open Stock Movers 06/30: (OCUP) (ASTS) (XELA) Higher; (ALT) (ECOR) (REPX) Lower (more...)

June 30, 2021 9:27 AM EDT

Pre-Open Stock Movers:

Ocuphire Pharma, Inc. (Nasdaq: OCUP) 40.6% HIGHER; announced that the VEGA-1 Phase 2 clinical trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects successfully met its primary and many secondary endpoints. On the strength of these results, Ocuphire plans to move into Phase 3. Given the rapid onset and sustained duration of efficacy, the favorable safety profile, and the potential tunability of... More

Cerevel Therapeutics (CERE) PT Raised to $30 at Goldman Sachs

June 30, 2021 9:13 AM EDT

Goldman Sachs analyst Graig Suvannavejh raised the price target on Cerevel Therapeutics (NASDAQ: CERE) to $30.00 (from $23.00) while maintaining a Buy rating.... More